An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2010
At a glance
- Drugs NSA 789 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 22 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Mar 2009 Additional location identified as reported by ClinicalTrials.gov, last updated 5 Mar 2009.